Plasma Purification Treatment Relieves the Damage of Hyperlipidemia to PBMCs

Frontiers in Cardiovascular Medicine

article

Xiao Meng Zhang¹  Yan Hong Gu¹  Hao Deng¹  Zheng Quan Xu²  Ze Yuan Zhong³  Xia Jie Lyu⁴  Hui Min Jin¹  Xiu Hong Yang¹ 

[1] Division of Nephrology, Pudong Medical Center, Shanghai Pudong Hospital, Fudan University;The First Affiliated Hospital of Medical School of Zhejiang University, Zhejiang University;Division of Orthopedic, Pudong Medical Center, Shanghai Pudong Hospital, Fudan University;School of Basic Medicine, Weifang Medical University

关键词: plasma purification;    PBMC;    lipid metabolism;    endoplasmic reticulum stress;    ROS;   

DOI  :  10.3389/fcvm.2021.691336

学科分类：地球科学(综合)

来源: Frontiers

【 摘 要 】

Background: Hyperlipidemia {hypercholesterolemia [cholesterol >5.18 mmol/L) or hypertriglyceridemia [triglycerides >2.3 mmol/L], mixed hyperlipidemia [cholesterol >5.18 mmol/L and triglycerides >2.3 mmol/L], and high low-density lipoproteinemia [low-density lipoprotein (LDL) >3.4 mmol/L]} is a strong risk factor for arteriosclerosis and cardiovascular disease (CVD). Therapy with lipid-lowering drugs often results in many side effects. Our study aimed to investigate the potential effects of non-drug therapy with double-filtration plasmapheresis (DFPP) on lipid metabolism-, endoplasmic reticulum (ER) stress-, and apoptosis-related proteins in peripheral blood mononuclear cells (PBMCs) before and after lipid clearance in patients with hyperlipidemia. Methods: Thirty-five hyperlipidemia patients were selected. Proteins related to lipid metabolism [CD36, proprotein convertase subtilisin/kexin type 9 (PCSK9), and LDL receptor], ER stress [glucose-regulated protein 78 (Grp78), C/EBP homologous protein (CHOP), activating transcription factor 4 (ATF4), and eukaryotic initiation factor 2α (EIF2α)], and apoptosis [B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (BAX), and cysteinyl aspartate specific proteinase-3 (Caspase-3)] were assayed by Western blot, reactive oxygen species (ROS) were measured by flow cytometry (FCM), and ELISA detected serum inflammatory [interleukin (IL)-1β, IL-6, and tumor necrosis factor α (TNF-α)] factors. Results: Compared with their pre-DFPP values, the values of most lipid metabolic parameters, such as cholesterol, triglycerides, LDL, lipoprotein a [Lp(a)], and small dense LDL (sdLDL) cholesterol, were reduced after DFPP. DFPP was associated with the downregulation of proteins related to lipid metabolism, ER stress, and apoptosis, resulting in decreased ROS and serum inflammatory factor release. Conclusion: DFPP has lipid-lowering activity and can also regulate lipid metabolism-, ER stress-, and apoptosis-related proteins in PBMCs and reduce the levels of inflammatory factors in patients with hyperlipidemia ( ClinicalTrials.gov number: {"type":"clinical-trial","attrs":{"text":"NCT03491956","term_id":"NCT03491956"}} NCT03491956 ).

【 授权许可】

CC BY